Abstract. Epidemiological methods are needed to evaluate community exposure to Borrelia burgdorferi, the causative agent of Lyme disease (LD). For LD serodiagnosis, the Centers for Disease Control and Prevention (CDC) recommends a 2-test approach that involves enzyme immunoassay (EIA) testing and Western immunoblotting (WB) of EIA-equivocal and EIA-positive specimens. The specificity of this approach was evaluated among residents of a LD-endemic community and was compared with WB alone and with a simplified 2-test approach (WB of equivocal EIA only). Participants reporting no previous diagnosis of LD were recruited during a community-wide serosurvey on Block Island, Rhode Island. Of 80 eligible participants, 20 had received LD vaccine. Seven (35%) of 20 vaccinees and 22 (37%) of 60 nonvaccinees reported nonspecific symptoms compatible with LD in the previous year. In this highly LD-endemic community, the overall specificity of the CDC-recommended approach was highest (100%), followed by WB alone (98.7%), then the simplified approach (95%).
INTRODUCTION
Lyme disease (LD), which is caused by the tick-borne spirochete Borrelia burgdorferi, is the most common vectorborne illness in the United States. 1 Lyme disease has a distinct geographical distribution, corresponding to the distribution of the tick vectors, Ixodes scapularis in the East and upper north-central regions, and I. pacificus in the Pacific Northwest. 2 Community levels of endemicity within these different regions are determined by complex environmental and personal behavioral factors that are difficult to measure. For public health purposes, sensitive and specific serologic tests are needed to determine accurately the level of exposure to B. burgdorferi.
The need for standardized methods for serologic diagnosis of LD has led the Centers for Disease Control and Prevention (CDC) to recommend a 2-test approach. 3, 4 Specimens are first tested by means of a sensitive enzyme immunoassay (EIA) or indirect immunofluorescence assay. Equivocal or positive serum specimens are then tested with the more specific immunoglobulin (Ig) M and IgG Western blot (WB). The rationale for WB of EIA-positive serum specimens was to maintain a high specificity, especially for testing serum from patients with nonspecific clinical findings, and for patients from areas not known to be LD endemic. 5 The specificity of the CDC-recommended approach has not been evaluated for community assessment in an area highly endemic for LD. Previous studies of healthy blood donors from the nonendemic states of Ohio and Illinois and of people living in nonendemic and low-endemic regions of Maine have found the CDC-recommended approach to be highly specific. 6, 7 A follow-up study of a high-risk population in a highly endemic area of New York found evidence of previous exposure and seroconversion to B. burgdorferi among symptomatic and asymptomatic people but did not estimate the specificity of the test. 8 In the current study, the specificity of the CDC-recommended approach was evaluated in a highly endemic area for LD and compared with 2 other testing approaches: a simplified 2-test approach (referred to here as the simplified approach), in which WB only follows equivocal EIA findings (and not positive EIA findings); and WB alone. 9 In addition to evaluating the results of serologic testing of asymptomatic people with no history of LD, we tested people with a history of nonspecific symptoms that could be associated with undiagnosed LD and people recently vaccinated for LD by a recombinant B. burgdorferi outer surface protein A (OspA). 10, 11 MATERIALS AND METHODS Selection of serosurvey participants. Serum specimens were obtained from voluntary participants in an annual tickborne disease serosurvey in Block Island, Rhode Island. The survey was conducted during the autumn of 1995 and spring of 1996. People of any age were eligible to be enrolled, providing they had resided on Block Island for at least 1 month during the 1995 B. burgdorferi transmission season. Participants were asked to complete a standardized questionnaire to collect information on personal risk factors, environmental exposures, illness history, and history of vaccination against LD during a recent vaccine clinical trial. People reporting a previous diagnosis of LD were excluded from the current study. People reporting a history of rash, fever, chills, myalgia, fatigue, joint pain, or joint swelling in the past year were considered to have nonspecific symptoms possibly associated with LD. People with no previous diagnosis of LD and no symptoms compatible with LD in the previous year were assumed to have not been infected with B. burgdorferi and were used as a negative reference standard. All participants or their guardians signed a written informed consent approved by the Connecticut Children's Medical Center institutional review board.
Serum specimens. Blood specimens were collected in serum separator tubes. Serum was placed in plastic tubes and frozen at the University of Connecticut Health Center Clinical Microbiology Laboratory within 24 hr of collection. Serum specimens were submitted to CDC in a coded, unlinked fashion for testing by a polyvalent (IgM/IgG) EIA (Vidas, BioMerieux Vitek, Hazelwood, MO) and for IgG WB (Marblot, MarDx Diagnostics, Carlsbad, CA) according to the manufacturers' instructions. Low-passage B. burgdorferi * EIA ϭ enzyme immunoassay. Participants who reported a history of rash, fever, chills, myalgia, fatigue, or joint pain and/or swelling in the past year were considered to be symptomatic.
strain B31 was used as the antigen source for both assays.
Because there was no objective clinical evidence for recent onset of LD in the participants, only IgG WB results were considered in the evaluation of serosurvey serum specimens. 4 In accordance with the CDC-recommended criteria for WB interpretation, serum specimens reacting with at least 5 of 10 IgG diagnostic bands by immunoblotting were considered positive. 4 The following antigens were also evaluated for IgG immunoblots, although they are not included in the above criteria: 60, 62, 37, 34 (OspB), and 31 kDa (OspA). The identity of specific antigens in immunoblots was facilitated by the use of reference monoclonal antibodies. 5 Data analysis. Data were entered in Microsoft Access (version 2.0; Redmond, WA) and imported into Epi Info (version 6.04b; CDC, Atlanta, GA) for descriptive epidemiologic analyses. Odds ratios (OR) and Fisher's exact 2-tailed probabilities and 95% confidence intervals (CI) were calculated by PEPI (version 2.07A, USD, Inc, Snellville, GA). For all statistical analyses, significance was defined as P Ͻ 0.05.
RESULTS
Serosurvey. Serum specimens were obtained from 80 serosurvey participants who had no previous diagnosis of LD; 20 had received LD vaccine as part of a vaccine clinical trial. Seven (35%) of 20 vaccine recipients and 22 (37%) of nonrecipients reported a history of rash, fever, chills, myalgia, fatigue, or swollen or painful joints in the previous year. The frequencies of self-reported symptoms and tick exposure by serosurvey participants are summarized in Table 1 .
The EIA results are presented in Table 2 . Vaccine recipients were not significantly more likely to be EIA positive than nonrecipients (OR, 3.2; 95% CI, 0.2-47; P ϭ 0.52).
The specificity for each of the testing approaches is presented in Table 3 . Sensitivity was not calculated because participants with a history of LD were excluded from this study. No specimens were positive by the CDC-recommended approach. Four specimens (5%) were positive by the simplified approach (all negative by WB) and one (1%) was positive by WB alone (negative by EIA); there was an insufficient quantity of serum from 3 (4%) participants to perform WB alone ( Table 3 ). The one person who was positive by WB alone had not been vaccinated and had no symptoms compatible with LD in the previous year. Only 1 of these 5 seroreactive people reported a history of a tick bite. This EIA-positive person was unvaccinated and reported a history of myalgia, fatigue, and headache in the previous year.
Western immunoblot reactivity. The frequency of WB reactivity to specific antigens is shown in Table 4 . The most common IgG antibody detected was to the 41-kDa antigen (flagellin), detected in 48.8% of serosurvey participants. As expected, the seroprevalence of IgG antibody to the 31-kDa antigen (OspA) was significantly higher among vaccine recipients than nonrecipients (OR, 84.3; 95% CI, 8.8-3,714; P ϭ 0.000).
DISCUSSION
The CDC-recommended LD serodiagnostic approach has not been previously evaluated in comparison with the simplified approach or WB alone for assessing community exposure to B. burgdorferi in an area highly endemic for LD. In 1995, the incidence of LD in Rhode Island was 34.9 per 100,000 population compared with the overall national incidence of 4.4 per 100,000 population. 12 A high specificity is critical for seroepidemiologic purposes. In the current study, the overall specificity was highest for the CDC-recommended approach (100%), followed by WB alone (98.7%) and the simplified approach (95%).
A previous study that examined serum specimens from healthy blood donors from nonendemic areas estimated the specificities of the CDC-recommended approach and the simplified approach to be 100 and 96%, respectively. 6 The EIA reactivity detected among these healthy blood donors was presumed to be due to false-positive results. In the current study, self-reported history of no previous LD and no symptoms compatible with LD in the previous year were used as a negative reference standard, although the possibility of asymptomatic infection cannot be ruled out. Only one specimen from this group was seroreactive (by WB alone), indicating very high specificity, low sensitivity for asymptomatic infection, or both, for the 3 testing approaches evaluated (Table 3 ). The single WB positive result may have * EIA ϭ enzyme immunoassay. Data are number negative/total tested. Patients who reported a history of rash, fever, chills, myalgia, fatigue, or joint pain and/or swelling in the past year were considered to be symptomatic.
† There was an insufficient quantity of serum from 3 study participants to perform the Western blot test alone. ‡ Western blot only follows EIA equivocals (and not EIA positives). (14) 1 (5) 2 (9) 3 (14) 1 (5) 11 (50) 2 (5) 3 (8) 1 (3) 3 (8) 
2 (2.6) 3 (3.9) 1 (1.3) 2 (2.6) * Data are reported as number (%) positive for band. Participants who reported a history of rash, fever, chills, myalgia, fatigue, or joint pain and/or swelling in the past year were considered to be symptomatic. There was an insufficient quantity of serum from 3 study participants to perform Western blot alone.
either been a false-positive result or evidence of a previous asymptomatic infection.
The current study supports other findings that demonstrate the utility of WB as a more specific second-tier test. 13, 14 The 4 people with positive results by the simplified approach reported a history of nonspecific symptoms in the previous year, indicating that nonspecific illness may be associated with a false-positive EIA result. The possibility of a falsenegative WB result seems less likely but cannot be ruled out. The pretest likelihood of LD is likely to be affected by the month of illness onset, given the seasonality of the disease. These data were not available in the current study to aid in the interpretation of the test results. However, specificity estimates for the CDC-recommended approach and WB alone would be unaffected by knowing the month of illness onset.
Seroepidemiologic studies have been conducted in areas of moderate or high endemicity. 7, 8, 15 However, no attempt was made in these studies to estimate the specificity of the CDC-recommended testing approach that used a reference standard based on clinical or any other criteria. A seroepidemiologic study in Maine identified 3 of 100 residents of a nonendemic area as positive by EIA and negative by WB, and 2 of 272 residents of a low endemic area who were positive by both EIA and WB, neither of whom had a history of tick bite, LD diagnosis, or current symptoms. 7 A study of 671 residents in a highly endemic area of New York found that 5% were positive by both EIA and WB at study onset and that 1% seroconverted, most with symptoms of LD, over the course of a year. History of symptoms or LD diagnosis were not reported for participants. 8 Residents of endemic areas with no symptoms of LD have provided estimates of the specificity of IgM but not IgG serologies. 14 These studies indicate that seroreactivity occurs in the absence of clinical evidence of LD, which may result from false-positive reactions or asymptomatic infections.
In the current study, the overall specificities of 100% for the CDC-recommended approach, 98.7% for WB alone, and 95% for the simplified approach are consistent with those observed in other studies. [6] [7] [8] It is noteworthy that the specificity of the CDC-recommended approach was 100%, regardless of history of vaccination or history of nonspecific symptoms in the previous year. Although the 36.3% of serosurvey participants who reported nonspecific symptoms may have had undiagnosed LD, the low rate of seroreactivity suggests that the actual rate of undiagnosed LD was low to nonexistent; undiagnosed LD was associated with a weak serologic response; or antibody levels in undiagnosed LD patients had waned by the time of this study.
Concerns have been expressed that LD vaccine use may lead to false-positive LD serologies. 10, 11, 16 In the current study, EIA responses in OspA vaccine recipients were not significantly different from nonrecipients, although the number of vaccinees was small. However, the seroprevalence of IgG antibody to OspA was significantly higher among vaccine recipients compared with nonrecipients. As noted in an earlier study, OspA reactivity did not interfere with interpretation of WB according to the CDC recommended criteria. 16 Data were unavailable to evaluate the relationship between the number of LD vaccine doses received or the timing of vaccination with EIA reactivity.
In summary, results of the current study provide further evidence of the utility of the WB as a specific second-tier test. The results also indicate a low prevalence of undiagnosed LD in people in a highly endemic area for LD who report only nonspecific symptoms.
